Eli Lilly and Company have announced that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe...
This resource outlines the key characteristics of Microscopic Colitis (MC) which is an inflammatory Bowel Disease that affects the large bowel (colon and rectum). The symptoms of Microscopic Colitis have some overlap with diarrhoea prominent Irritable Bowel Syndrome...
Celltrion Healthcare have announced two new data sets relating to the use of the subcutaneous formulation of infliximab, Remsima® SC (CT-P13 SC), in inflammatory bowel disease (IBD) at a poster presentation at UEG Week Virtual 2020. The first study investigated the...
The Janssen Pharmaceutical Companies of Johnson & Johnson have released Phase 2 interim data from the GALAXI 1 study, which showed TREMFYA® (guselkumab) demonstrated results at week 12 in adult patients with moderately to severely active Crohn’s disease (CD) with...
Topline results have been releases from a phase III study programme evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. Mixed results were seen in studies evaluating etrolizumab as an induction therapy,...
